Grown Rogue International (GRUSF) Total Non-Current Liabilities (2009 - 2026)
Grown Rogue International's (GRUSF) quarterly Total Non-Current Liabilities came in at $2.9 million in Q1 2026, down 89.49% year-on-year from $27.7 million in Q1 2025, and down 3.0% quarter-over-quarter from $3.0 million in Q4 2025.
Grown Rogue International (GRUSF) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Grown Rogue International's Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 89.49% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $2.9 million, a 89.49% decrease from a year earlier, with the FY2025 full-year figure at $3.0 million, down 51.78% from the prior year.
- Total Non-Current Liabilities eased to $2.9 million in Q1 2026 per GRUSF's latest filing, from $3.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $19184167000.0 billion in Q2 2025 and bottomed at -$193195.5 in Q4 2024.
- The 5-year median for Total Non-Current Liabilities is $2.9 million (2026), against an average of $2131576667.2 billion.
- Across the five-year window, Total Non-Current Liabilities sank 134.47% in 2024 and jumped 1652.92% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $715461.0 in 2022, then decreased by 21.67% to $560425.0 in 2023, then sank by 134.47% to -$193195.5 in 2024, then soared by 1652.92% to $3.0 million in 2025, then retreated by 3.0% to $2.9 million in 2026.
- Per Business Quant, the three latest GRUSF Total Non-Current Liabilities figures stand at $2.9 million (Q1 2026), $3.0 million (Q4 2025), and $23005.2 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | 2.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.91 Mn |
| Dec 31, 2025 | 3.00 Mn |
| Sep 30, 2025 | 23,005.21 Bn |
| Jun 30, 2025 | 19,184,167,000.00 Bn |
| Mar 31, 2025 | 27.68 Mn |
| Dec 31, 2024 | -193,195.51 |
| Dec 31, 2023 | 560,425.00 |
| Oct 31, 2023 | 253,340.00 |
| Oct 31, 2022 | 715,461.00 |
| Oct 31, 2021 | 1.23 Mn |
| Oct 31, 2020 | 68,994.00 |
| Aug 31, 2018 | 63,212.58 |
| May 31, 2018 | -572,977.84 |
| Feb 28, 2018 | -573,520.90 |
| Nov 30, 2017 | -558,401.76 |
| Aug 31, 2017 | -170,845.96 |
| May 31, 2017 | -2.10 Mn |
| Feb 28, 2017 | -2.13 Mn |
| Nov 30, 2016 | -2.09 Mn |
| Aug 31, 2016 | -1.35 Mn |